EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today the completion of the in-life portion of its two pivotal Phase 3 clinical trials for Puricase® (pegloticase) in patients with treatment-failure gout, an orphan indication. Puricase is a pegylated recombinant mammalian urate oxidase that is being developed to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. At this time there is no alternative therapeutic option for the management of treatment-failure gout patients other than symptomatic relief.
